First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma Collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK ("SAKK") to conduct a Phase 2 randomized, study in early-stage breast cancer in Europe Cash and investments of $6.3 million expected to fund operations into the first quarter of 2025 SHELTON, Conn., Aug. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology com ...

Financial Data and Key Metrics Changes - The company reported a quorum of 8,522,652 shares present, representing 62.15% of the outstanding voting stock [6] - Preliminary results indicated that a majority of votes were cast in favor of the election of directors and the approval of the employee stock purchase plan [10][11] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed in the provided content Market Data and Key Metrics Changes - No specific market data or key metrics were discussed in the provided content Company Strategy and Development Direction and Industry Competition - The company is focused on improving stockholder access by conducting meetings virtually [2] - The company has proposed an employee stock purchase plan to enhance employee engagement and investment in the company [11] Management's Comments on Operating Environment and Future Outlook - Management indicated that forward-looking statements may differ significantly from actual results due to various factors, including those outlined in SEC filings [13] Other Important Information - The meeting was held virtually to enhance accessibility for stockholders [2] - The appointment of Eisner Amper LLP as auditors for fiscal year 2024 was ratified [11] Q&A Session Summary - No questions were received during the Q&A session, and it was subsequently closed [13]

Testing the efficacy and safety of our lead product candidate, INT230-6, as Monotherapy Compared with Systemic U.S. Standard-of-Care Chemotherapy "We have now dosed our first patient in the U.S. and have filed regulatory documents to initiate this trial in Canada and Europe. Over the next several months, we anticipate initiating sites in eight countries. Sarcoma is a deadly cancer with a median overall survival following second and third-line drug treatments of between 10 and 15 months," said Intensity Ther ...

SHELTON, Conn., May 15, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces the appointment of Thomas Dubin, J.D., MPH, to the Intensity Board of Directors, effective May 14, 2024. Mr. Dubin will serve as a member of the Audit Commi ...

Exhibit 99.1 Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Shelton, CT, May 9, 2024 – Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces first quarter 2024 financial results and provides a corporate u ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 001-41109 INTENSITY THERAPEUTICS, INC. (Exact name of registrant a ...

Summary of Intensity Therapeutics (INTS) Conference Call - April 09, 2024 Company Overview - Intensity Therapeutics is focused on developing innovative cancer therapies using a unique intratumoral delivery technology that aims to enhance immune response against tumors [2][3][4] Key Points and Arguments Innovative Drug Delivery Technology - The company utilizes an oral form of Ozempic with a unique delivery mechanism that allows for intratumoral drug administration, leading to a new immunological approach to cancer treatment [2][3] - The drug is a water-based formulation that can effectively diffuse through fat-dense tumor environments, enhancing absorption [5][6] Clinical Trials and Studies - Over 200 patients have been treated in studies, with a Phase 3 study for metastatic sarcoma expected to begin in mid-2024 [3][7] - The company has received FDA orphan drug status, providing advantages in regulatory processes and potential market exclusivity [8] - The metastatic sarcoma market consists of approximately 157,000 patients in the U.S., with a median survival of only 13-14 months [9] Treatment Efficacy - Preliminary data suggests that the drug can significantly increase median survival from 3 months to 18 months in patients who have failed previous therapies [13][20] - In a breast cancer study involving 91 patients, the drug achieved 95% necrosis in tumors without affecting cosmetic outcomes post-surgery [25][26] Safety Profile - The treatment has shown a favorable safety profile, with less than 10% of patients experiencing grade three adverse events, primarily mild pain and fatigue [18] Market Potential and Future Plans - The company plans to initiate two major studies: one for metastatic sarcoma and another for triple-negative breast cancer, with hopes to complete enrollment by Q3 2025 [28][34] - The company has $14.8 million in cash and no debt, indicating a solid financial position to support upcoming studies [28] Additional Important Information - The drug aims to activate the immune system against tumors that are typically non-immunogenic, potentially transforming the treatment landscape for various cancers [10][11] - The company emphasizes the importance of personalized treatment based on tumor size rather than a one-size-fits-all approach [12] - The management team has a strong background in drug development, and the company has established partnerships with leading cancer research institutions [5][32] Conclusion - Intensity Therapeutics is positioned to potentially revolutionize cancer treatment with its innovative drug delivery technology and promising clinical results, focusing on improving patient outcomes and quality of life while addressing significant unmet medical needs in oncology [29][30]

Exhibit 99.1 Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update Shelton, CT, March 14, 2024 – Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces full year 2023 financial results and provides a review of 2023 a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41109 INTENSITY THERAPEUTICS, INC. (Exact name of registrant as specified in its charte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41109 Intensity Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | ...